Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Like many here ( I presume ) I have a core holding and will try and trade on the dips and looks like it’s getting close to my next buy in point. Still happy here long term but you won’t here me critical of the company to try and aid my position.
Major therapeutics development partnership and licensing agreement with LG Chem Life Sciences (LG Chem). Potentially generating revenues for Avacta of up to $310 million, plus future royalties on product sales, the agreement included an upfront payment of $2.5 million, pre-clinical milestone payments of up to $5.5 million plus payment of Avacta’s full research costs to generate Affimer molecules for the treatment of a range of diseases.
As below from the RNS there are still nearly 300 million more to come so we shouldn’t be surprised and hopefully they will all be exercised as I see that as a positive and will add another £2 million ish to ORRs coffers.... my bed is dry !!
Following Admission, a total of 208,385,020 warrants and 81,642,912 options over Ordinary Shares (representing approximately 18.4 per cent. of the Company's enlarged issued share capital) remain outstanding.
Just been informed that after a year of arriving in Aberdeen a day early to get PCR test before going offshore next day, from 31st May we are now going to get a rapid test done on the morning of our departure and can only guess it’s not a crappy Innova test !!
I liked this but in the RNS below the contacts:-
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.
Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.
Probably get another speeding ticket saying we know of no reason for the current 20% rise apart there is shiit loads of gold around our claims and it doesn’t take a rocket scientist to realise we will have loads too .....
My favourite bit of RNS:-
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"The potential for AffyXell's new class of MSC therapies to deliver improved treatments for a wide range of inflammatory and autoimmune diseases is significant, in a market estimated to be worth $16bn by 2025. We expect these novel engineered MSCs to show a more powerful therapeutic effect than existing antibodies and stem cells and they therefore have the potential to lead the rapidly growing field of cell and gene therapy.
and this current spread won’t matter when news of further contracts are announced !! GLA